MPI Announces registration of trademark for DRP

2017-11-01

Hoersholm, Denmark, November 1, 2017 - Medical Prognosis Institute A/S (MPI.ST) today announced that the United States Patent & Trademark Office (USTPO) has allowed and registered its primary trademark, DRP®, used in connection with the Company's core predictive biomarker platform and services.  

The DRP® biomarker platform uses tumor mRNA and proprietary analytics to develop tumor-derived genetic signatures, which are used to identify which cancer patients are likely to respond to a given anti-cancer drug.  This proprietary technology has been validated in over 37 clinical studies to date.
Drug-specific DRP® biomarkers are being used as companion diagnostics (CDx) for Phase 2 anti-cancer drugs in development at Oncology Venture Sweden AB (OV.ST) and U.S.-based 2X Oncology.  The CDx is used to identify and select likely responder patients for inclusion in relevant clinical trials. This precision medicine approach is expected to enable personalized oncology treatments for all cancer types including breast, ovarian, prostate and pancreatic cancers and multiple myeloma which are the initial foci for the use in drug development.

About MPI's Drug Response Predictor - DRP®
MPI's DRP® is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP® has been tested in 37 trials, where 29 trials showed that drug-specific DRP® Biomarkers could predict which patients responded well to the treatment. The DRP® platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP® method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP® builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is a Big Data tool based on messenger RNA.
The DRP® platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP® technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP® tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:
CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                      E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49